Dr. David M. Huffman, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 521
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
TN license TNMD19974
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Healthcare System, Inc Chattanooga, TN
- Erlanger Medical Center Chattanooga, TN
Medical groups
- David M. Huffman, M.d.,p.c. (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 521
- Services billed
- 3,530
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 1,314 | 549 |
| Hemoglobin a1c level | 925 | 391 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 763 | 285 |
| Blood glucose (sugar) test performed by hand-held instrument | 325 | 169 |
| Ultrasound scan of head and neck soft tissue | 51 | 50 |
| Established patient office or other outpatient visit, 30-39 minutes | 48 | 43 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | 29 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Chattanooga, TN | 383 |
| Mounjaro (tirzepatide) Other prescribers in Chattanooga, TN | 339 |
| Synthroid (levothyroxine sodium) Other prescribers in Chattanooga, TN | 279 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Chattanooga, TN | 233 |
| Ozempic (semaglutide) Other prescribers in Chattanooga, TN | 178 |
| Jardiance (empagliflozin) Other prescribers in Chattanooga, TN | 144 |
| Armour Thyroid (thyroid,pork) Other prescribers in Chattanooga, TN | 112 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Chattanooga, TN | 99 |
| Atorvastatin Calcium Other prescribers in Chattanooga, TN | 87 |
| Novolog Flexpen (insulin aspart) Other prescribers in Chattanooga, TN | 72 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 32 companies reported 209 payments worth $21,666 in total to this clinician.
| Novo Nordisk Inc | $17,277 |
|---|---|
| Cequr Corporation | $604 |
| Amgen Inc. | $421 |
| Medtronic, Inc. | $345 |
| Sequel Med Tech, LLC | $329 |
| Insulet Corporation | $309 |
| AbbVie Inc. | $232 |
| Xeris Pharmaceuticals, Inc. | $217 |
| Compensation for services other than consulting (speaking, faculty) | $12,177 |
|---|---|
| Food and Beverage | $5,003 |
| Consulting Fee | $2,790 |
| Travel and Lodging | $1,675 |
| Education | $20.22 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $5,638 |
| Novo Nordisk Inc Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $3,023 |
| Novo Nordisk Inc Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $2,093 |
| Novo Nordisk Inc Oct 10, 2025 | Consulting Fee Multiple Therapeutic Areas Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,395 |
| Novo Nordisk Inc Oct 9, 2025 | Consulting Fee Multiple Therapeutic Areas Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,395 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $1,119 |
| Novo Nordisk Inc Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $930 |
| Novo Nordisk Inc Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $494 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $399 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $145 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Oct 10, 2025 | Consulting Fee Multiple Therapeutic Areas Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,395 |
| Novo Nordisk Inc Oct 9, 2025 | Consulting Fee Multiple Therapeutic Areas Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $1,395 |
| Novo Nordisk Inc Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $494 |
| Novo Nordisk Inc Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $930 |
| Medtronic, Inc. Jun 21, 2025 | Travel and Lodging MINIMED 780G · Durable Pump · travel to Chicago, IL · in-kind | $12.42 |
| Novo Nordisk Inc Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $3,023 |
| Novo Nordisk Inc Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $2,093 |
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $5,638 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $1,119 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $399 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $145 |
| Bayer HealthCare Pharmaceuticals Inc. Jan 9, 2025 | Education Kerendia · Cardio-Renal · in-kind | $20.22 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $195,355 in research payments for these studies, mostly to the institutions running them.
- Innovative Automated Insulin Delivery System for Type 2 Diabetes
Sequel Med Tech, LLC · Completed · NCT06853990 - Study name not reported
Novo Nordisk As - Study name not reported
Novo Nordisk As
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.